Today: 30 April 2026
Browse Category

NYSE:NVO 21 September 2025 - 6 November 2025

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

A Delaware court denied Pfizer’s request to block Metsera from ending their merger deal in favor of Novo Nordisk’s higher bid. Pfizer plans to raise its offer after Novo’s proposal reached up to $10 billion. FTC staff warned Novo’s bid structure could violate pre-merger rules. Pfizer shares traded near $24.61 midday Thursday.
6 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Novo Nordisk cut its 2025 sales and profit outlook for the fourth time this year after third-quarter results missed forecasts, with Wegovy revenues below expectations. Operating profit fell 30% due to restructuring costs. The company faces rising competition from Eli Lilly and U.S. copycat drugs, as well as mounting pricing pressure. Shares have dropped up to 50% in 2025; Novo plans 9,000 job cuts and a $10 billion bid for Metsera.
5 November 2025
···
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera shares jumped nearly 20% to $73.29 on November 4, 2025, hitting a 52-week high after Novo Nordisk raised its takeover offer to $86.20 per share, topping Pfizer’s $70 bid. Metsera’s board called Novo’s proposal “Superior.” A Delaware judge declined to halt the bidding war, fueling further gains. Pfizer has until midweek to counter Novo’s offer.
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer shares traded near $24.60 on Nov. 4, 2025, down about 8–9% year-to-date and over 60% from their 2021 peak. Q3 adjusted earnings beat forecasts at $0.87 per share, but revenue missed slightly at $16.65 billion. Pfizer raised its full-year profit outlook and reaffirmed revenue guidance. The company is locked in a takeover battle with Novo Nordisk for obesity drug developer Metsera.
4 November 2025
·····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk raised its offer for Metsera to about $10 billion, topping Pfizer’s $8.1 billion bid. Metsera’s board labeled Novo’s bid “superior,” triggering a two-day window for Pfizer to respond. Pfizer has filed lawsuits in Delaware and federal court to block Novo’s challenge. Shares in Metsera jumped 20% after the news, while Novo’s stock slipped.
4 November 2025
···
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer reported Q3 2025 adjusted earnings of $0.87 per share, beating estimates, with revenue at $16.65–$16.7 billion. The company raised its full-year profit outlook to $3.00–$3.15 EPS. Sales of COVID products plunged, but demand for Eliquis and Vyndaqel rose. Pfizer sued Novo Nordisk over a $7.3 billion bid for obesity drugmaker Metsera; a court hearing is set for Nov. 4.
4 November 2025
···
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 November 2025
·······
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Novo Nordisk made an unsolicited $8.5 billion bid for Metsera, topping Pfizer’s earlier $7.3 billion deal. Metsera’s board called Novo’s offer “superior,” triggering a four-day window for Pfizer to respond. Metsera shares jumped over 18% on the news, while Novo’s stock fell 3%. Pfizer criticized Novo’s move as “reckless,” warning it could suppress competition.
31 October 2025
····
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Novo Nordisk launched a hostile bid for Metsera on Oct. 30, 2025, offering up to $9 billion and topping Pfizer’s earlier $7.3 billion deal. Metsera shares jumped about 19% in premarket trading. The board called Novo’s offer “superior,” giving Pfizer four days to respond. A law firm began investigating whether the original Pfizer deal was fair to shareholders.
30 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk launched an $8.5 billion unsolicited bid for obesity drugmaker Metsera, topping Pfizer’s $7.3 billion agreed deal. Novo’s offer values Metsera at $56.50 per share in cash plus up to $21.25 in milestone payments. Metsera shares jumped 18% premarket, while Novo’s stock fell 3%. Pfizer called Novo’s bid “reckless” and warned it could harm competition.
30 October 2025
····
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Over 62,000 pharmaceutical professionals from more than 170 countries are attending CPHI Frankfurt 2025, where executives are meeting to address global supply chain, regulation, and innovation challenges. Eli Lilly’s GLP-1 drugs generated $6.1 billion in Q1 2025, overtaking Novo Nordisk in the U.S. weight-loss drug market. Pharma giants are investing heavily as the global obesity treatment market is projected to reach $100 billion by 2030.
28 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk shares closed at $54.78 on Oct. 21, down nearly 50% in 2025 and wiping out about $70 billion in market value. The Novo Nordisk Foundation forced a board overhaul, with chair Helge Lund and six directors to be replaced. Novo announced deals to buy Akero for up to $5.2 billion and license Omeros’ OMS906 for up to $2.1 billion. U.S. price pressure and Eli Lilly’s competition have weighed on investor sentiment.
22 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Novo Nordisk shares fell 6.7% in Copenhagen on Oct. 17, 2025, and U.S. pre-market quotes pointed to a further 4.8% drop. The stock has lost over 40% year-to-date, erasing hundreds of billions in value. Recent acquisitions and job cuts have not reversed investor caution, as competition from Eli Lilly intensifies and analysts warn of more profit downgrades.
17 October 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros shares soared about 146% on Oct. 15, 2025, closing near $10.11 after Novo Nordisk agreed to license its drug zaltenibart for up to $2.1 billion. Omeros will receive $340 million upfront, with the deal expected to close in Q4. The company will now focus on its lead drug narsoplimab, which is under FDA and EMA review. Analyst targets for Omeros stock range from $9 to $36.
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk will pay up to $2.1 billion to license Omeros’s experimental MASP-3 inhibitor zaltenibart for rare blood and kidney disorders. Omeros receives $340 million upfront, with additional milestone and royalty payments possible. Omeros shares jumped about 65% on the news, while Novo’s stock fell 1.5%. The deal is expected to close by Q4 2025.
15 October 2025
···
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero shares jumped nearly 19% to $55 on October 9, 2025 after Novo Nordisk announced a $5.2 billion buyout at $54 per share plus a $6 contingent payment. Novo will pay $4.7 billion upfront and another $500 million if Akero’s lead drug, efruxifermin, wins FDA approval by 2031. The deal has board approval and is expected to close by late 2025, pending regulatory and shareholder clearance.
9 October 2025
···
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, paying $54 per share in cash plus a potential $6 per share if Akero’s lead drug wins U.S. approval by 2031. Akero’s efruxifermin, in Phase 3 trials for fatty liver disease, has shown reversal of liver fibrosis in mid-stage studies. Akero shares jumped 19% on the news, while Novo shares were little changed. The deal is expected to close by year-end.
9 October 2025
··
Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

European stocks hit three-week lows Thursday, then rebounded Friday as the STOXX 600 fell 0.7% before rising 0.3%. U.S. President Trump’s new tariffs on drugs and trucks triggered a 2% drop in major pharma and truck stocks. The Bank of England warned on persistent UK inflation, while the ECB and Swiss National Bank held rates steady. Germany’s consumer confidence improved; Spain’s GDP beat forecasts.
26 September 2025
········
Weekend Science Bonanza: Breakthroughs From Space to Superbugs

Weekend Science Bonanza: Breakthroughs From Space to Superbugs

NASA confirmed its 6,000th exoplanet discovery, while astronomers observed a black hole speeding away at over 50 km/s after a merger. A weight-loss pill version of Ozempic led to 16% body weight loss in trials, and a quick EEG test detected early Alzheimer’s. Engineers nearly doubled refrigeration efficiency with nano-thin films. AI designed viruses that killed drug-resistant E. coli in lab tests.
21 September 2025
···
1 … 4 5 6 7

Stock Market Today

  • Social Security Faces 2033 Benefits Cliff Amid Debate Over S&P 500 Gains
    April 30, 2026, 12:13 PM EDT. A 64-year-old retiree's claim that Social Security payroll taxes could have grown into a $4 million S&P 500 investment revives debates on the program's future. The Old-Age and Survivors Insurance Trust Fund (OASI) is projected to run dry by 2033, with only 77% of scheduled benefits payable thereafter. Unlike investment accounts, Social Security funds are invested conservatively in U.S. government securities to minimize risk. Experts warn shifting to stock market investments could raise fees and add volatility, risking the system's reliability. The core issue remains solvency, as the system faces increasing financial pressure amidst uncertain market conditions and global events.

Latest article

Social Security’s $4 Million Question: Can the S&P 500 Beat a 2033 Benefits Cliff?

Social Security’s $4 Million Question: Can the S&P 500 Beat a 2033 Benefits Cliff?

30 April 2026
A retiree’s claim that Social Security payroll taxes could have grown to $4 million in the S&P 500 has renewed debate over the system’s structure. The Social Security Administration projects its main trust fund will be depleted by 2033, with incoming revenue covering 77% of benefits. The fund invests only in government securities, not stocks. The payroll tax rate is set at 12.4% of earnings up to $184,500 in 2026.
Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

30 April 2026
FatPipe shares jumped 18% to $2.92 Thursday after the company announced expanded access to its SD-WAN and cybersecurity products through public-sector procurement channels. The move follows a VeloCloud replacement program targeting customers of Arista Networks’ SD-WAN business. Trading volume reached 42.2 million shares. Investors remain cautious over execution and customer concentration risks.
Go toTop